Phase 1Recruiting

Renal Impairment Study for Oral EC5026

Assessment of Single Dose Pharmacokinetics of Oral EC5026 in a Population With Chronic Kidney Disease

Sponsor
EicOsis Human Health Inc. (Industry)
Enrollment
18 planned
Conditions
Chronic Kidney Disease
Interventions
EC5026 oral tablet
Ages
adults, older adults
Registry
NCT07694544

Full record on ClinicalTrials.gov

From the registry

The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1. To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD differs from age-matched healthy participants with normal kidney function. 2. To determine if a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD is safe and well tolerated. Researchers will compare a single 8 mg dose of oral across participants with varying degrees of kidney function impairment (either normal kidney function, or stage 3b chronic kidney disease \[CKD\], or state 4/5 CKD). Participants will be asked to take a single oral dose of EC5026 and will be monitored with PK laboratory assessments and safety assessments (including physical exams, vital signs, electrocardiograms, and others).

Primary outcomes

  • Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)
  • Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)
  • Maximum observed plasma concentration (Cmax)
  • Time to the maximum observed concentration of the drug (Tmax)

History

  1. Study completion expected

  2. Primary completion expected

  3. Registered

  4. Started